Lawmakers blasted insulin makers and pharmacy benefit managers at the House Energy and Commerce subcommittee hearing on insulin prices April 10, according to STAT.

Now that two of Gilead Science's lucrative, older drugs have lost patent protection, the drugmaker will lay off about 20 percent of its sales team, according to STAT.

Federal prosecutors have charged U.K. drugmaker Indivior with orchestrating a fraud scheme to boost prescriptions of its opioid-addiction treatment Suboxone Film, the U.S. Justice Department announced April 9.

Mergers and acquisitions are reshaping the pharmacy and pharmacy benefit manager industries, and the big players are gaining even more market share.

Bayer AG, which previously announced its intent to cut 12,000 positions worldwide, will eliminate about 4,500 of those positions in its home market of Germany, according to Bloomberg.

Pharmacy benefit managers stepped in to help manage prescription claims for insurers when coverage expanded under the ACA and with the creation of the Medicare Part D program.

Hours before one of its top executives was set to testify at a House hearing on insulin prices, Sanofi introduced a program that will lower the drug's cost for some patients.

Cost containment, collaboration and inventory visibility are top of mind for many pharmacy and supply chain management leaders.

Walgreens is partnering with VillageMD to open several primary care clinics in Houston.

Five executives from top pharmacy benefit managers in the U.S. testified before the Senate Finance Committee April 9.